Comparability Protocols for Site Transfers for Biologic Programs: Getting the Strategy Right Before the Change Begins

Comparability Protocols for Site Transfers for Biologic Programs: Getting the Strategy Right Before the Change Begins

Comparability Protocols for Site Transfers for Biologic Programs: Getting the Strategy Right Before the Change Begins

A manufacturing site transfer is one of the most consequential CMC changes a biologic program will face. Whether driven by capacity constraints, commercial scale-up, CDMO transitions, policy changes favoring changes to domestic sites or supply chain strategy, a site transfer introduces new equipment, new personnel, new environmental conditions, and often process differences that must be carefully evaluated before the transferred product can be used in clinical studies or released to the commercial market.

The regulatory mechanism for managing this evaluation is the comparability exercise, governed by ICH Q5E and supported by FDA’s 2022 guidance on comparability protocols for post-approval changes. When designed and executed well, a comparability protocol transforms a complex and potentially high-risk change into a predictable, well-governed process with an agreed regulatory pathway. When designed poorly or treated as an afterthought, it becomes a source of information requests, delayed timelines, and
in many cases, clinical supply disruptions.

Why Site Transfers Are a Distinct Comparability Challenge

Not all manufacturing changes are equal from a comparability standpoint. A site transfer is among the more complex because it typically involves simultaneous changes across multiple dimensions: different equipment train, different utilities, different operator procedures, potentially different raw material suppliers, and sometimes different processes and process scales. Each of these variables has the potential to affect product quality attributes, and the cumulative effect of multiple simultaneous changes is
harder to characterize than a single discrete change.

For biologics specifically, the relationship between the manufacturing process and product quality is direct and consequential. Subtle differences in cell culture conditions, purification column performance, or filtration parameters can affect glycosylation profiles, charge variant distribution, aggregation propensity, and other CQAs that bear directly on safety and efficacy. A site transfer comparability protocol must be designed to detect these differences, not simply confirm that the product meets its existing specifications.

This distinction matters. Release specifications are designed for quality control, not for detecting process-related differences. A comparability exercise that tests only specification-listed attributes will miss changes in higher-order structure, glycan profiles, or aggregation behavior that may not be visible in routine testing but are highly relevant to comparability. Therefore, a comparability protocol must go beyond the specification.

What a Well-Designed Site Transfer Comparability Protocol Includes

A comparability protocol for a site transfer is a prospective document and it should be finalized and ideally submitted to FDA before the first batch is manufactured at the new site. Its purpose is to define, in advance, exactly how comparability will be assessed and what constitutes an acceptable outcome. This prospective design is what gives the protocol its regulatory value: both the sponsor and the agency have agreed on the rules before the game is played.

A comparability assessment for a site transfer evaluates three categories of analytical assessment, each with its own pre-defined acceptance criteria, and together they form the complete evidentiary basis for a comparability conclusion:

  • A) Characterization attributes assessed through an extended analytical panel, 
  • B) Release attributes tested against both specification limits and a tighter comparability range derived from sending site history, and 
  • C) Stability attributes evaluated for both initial time point comparability and degradation rate similarity over time.

A well-designed site transfer comparability protocol for a biologic should include the following elements:

  • Description of the change: A clear description of what is being transferred, from which site, to which site, and whether the transfer is a full replacement or an addition of a new manufacturing location alongside the existing one. If both sites will remain active post-transfer, the protocol should address how commercial supply will be managed across both.
  • Risk assessment: A systematic evaluation of which CQAs are potentially affected by the site change / related changes and why. For each CQA, the risk assessment should consider the sensitivity of that attribute to the specific process differences introduced by the new site. An attribute that is highly sensitive to a process step that is changing at the new site warrants the most intensive comparability testing. An attribute that is primarily controlled by a step being replicated identically warrants less, but only because the step is unchanged, not because of where it sits in the manufacturing process.
  • Analytical testing plan: A comprehensive head-to-head comparison of pre- and post-transfer material covering the full range of physicochemical, structural, and functional attributes. For a monoclonal antibody, this typically includes primary structure confirmation, higher-order structure assessment, glycan profiling, charge variant distribution, aggregation and particle analysis, potency, and Fc effector function where relevant. Orthogonal methods should be used for high-risk attributes to provide independent lines of evidence. While the specific attributes vary by modality, the same risk-based principles apply across all biologic types. For recombinant enzymes, potency defined by enzymatic activity is typically the primary focus. For ADCs, the comparability panel must extend beyond the mAb characterization to cover DAR distribution, conjugation site consistency, and free drug levels. For viral vector-based gene therapies, vector genome titer, full-to-empty capsid ratio, and transduction efficiency replace glycosylation and charge variants as the primary comparability attributes. The analytical plan should always be tailored to the specific modality and the attributes most likely to be affected by the process steps changing at the new site. It is critical that the same analytical methods are used at both the sending and receiving sites for the head-to-head comparison. Method differences between sites introduce a variable that cannot be separated from product differences, undermining the integrity of the comparability conclusion. Where site-specific method transfers are required, method equivalency should be established before comparability testing begins.
  • Batch plan: The protocol should specify the number and scale of pre-transfer reference batches and post-transfer comparability batches to be included. For a commercial site transfer, at least three post-transfer batches at commercial scale is a widely accepted standard. The protocol should also define the manufacturing timeframe and any restrictions on when pre-transfer material may have been manufactured to remain relevant as a reference.
  • Pre-defined acceptance criteria: Specific, objectively assessable criteria for each attribute in the testing plan. Acceptance criteria should distinguish between attributes where the expectation is equivalence within a defined statistical range, attributes where a directional trend would be acceptable if within a justified boundary, and attributes where any difference would require further evaluation before proceeding. Pre-defined acceptance criteria should be established prospectively for three categories of attributes. For characterization attributes, criteria are typically set as a statistical reference range derived from sending site batch history; the more batches included, the more defensible the range. For release attributes, two levels apply: specification compliance as a minimum requirement, and a tighter comparability range derived from sending site batch history to confirm true comparability rather than simply passing release. For stability attributes, criteria should address both initial time point comparability and degradation rate similarity over time. The protocol should also specify which stability time points are required before the change can proceed, with longer-term real-time data committed as a post-implementation update.

Regulatory Submission Timing and Strategy

For post-approval site transfers under an approved BLA, the comparability protocol is typically submitted as part of a Prior Approval Supplement (PAS) under the two-step framework described in FDA’s 2022 guidance. In Step 1, the sponsor submits the comparability protocol for agency review and approval before manufacturing begins at the new site. In Step 2, the sponsor submits the completed comparability data package, and if acceptance criteria are met, the change can proceed under a reduced reporting category relative to what would apply without an approved protocol.

For development-stage programs, the comparability protocol framework applies whenever a site transfer occurs between clinical phases, particularly when material from the new site will be used in a pivotal clinical trial. FDA expects sponsors to demonstrate comparability between clinical material and commercial material, and a site transfer that occurs between Phase 2 and Phase 3 requires particular care to ensure that the pivotal trial material is linked to both the development history and the intended commercial process.

EMA follows the same ICH Q5E framework but manages site transfer changes through its variation classification system. A major site transfer typically requires a Type II variation, which requires prior approval before implementation. An approved comparability protocol can in some cases support a reduced variation category at the implementation stage, consistent with ICH Q12 PACMP principles.

Common Pitfalls in Site Transfer Comparability

  • Testing only to specification: As discussed above, release specifications are not designed to detect the kinds of differences that can result from a site transfer. A protocol that limits its analytical scope to specification-listed attributes is not a comparability protocol. It is a release testing summary. The extended characterization panel is essential.
  • Inadequate reference material: The pre-transfer reference material must be representative of the established process at the originating site. Batches manufactured under non-routine conditions, at non-representative scales, or outside the normal process range should not serve as the primary comparability reference. Sponsors should plan reference batch selection carefully and document the rationale.
  • No pre-defined acceptance criteria: Defining what constitutes comparability after the data is generated is not a comparability protocol. It is a post-hoc justification, and regulators treat it accordingly. Acceptance criteria must be established prospectively before the first post-transfer batch is manufactured.
  • Late planning: The comparability protocol should be developed in parallel with the site transfer itself, not after manufacturing has begun. Sponsors who start manufacturing at a new site before a protocol is in place may find themselves unable to use the data generated from early batches to support the regulatory submission because the testing plan and acceptance criteria were not agreed in advance.

Final Thoughts

A site transfer comparability protocol is not a bureaucratic requirement. It is a scientific and regulatory tool that, when designed well, gives both the sponsor and the agency confidence that a consequential manufacturing change has been managed with rigor and foresight. The investment in a well-designed protocol, made before the first batch at the new site is manufactured, consistently pays dividends in smoother regulatory review, faster implementation timelines, and a clinical / commercial supply chain that is not held hostage to avoidable information requests.

At Spark CMC Consulting Corp, we support biologic sponsors through site transfer comparability strategy and protocol development, from risk assessment through data package preparation and regulatory submission under IND/IMPD, NDA and BLA. If your program is planning a site transfer and the comparability strategy is not yet in place, let us talk.


👁 633 views